Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$885.55 USD

885.55
1,951,041

-5.52 (-0.62%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Company News for Dec 10, 2020

Companies In The News Are: UNFI,CATM,FEYE,LLY

Eli Lilly (LLY) Soars: Stock Adds 5.8% in Session

Eli Lilly (LLY) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Roche (RHHBY), Moderna Ink Deal for Coronavirus Antibody Test

Roche (RHHBY) partners with Moderna to allow the latter utilize its Elecsys Anti-SARS-CoV-2 S antibody test in the mRNA-1273 vaccine research studies.

Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC

The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.

Lilly (LLY)/UnitedHealth Launch COVID-19 Study on Bamlanivimab

The pragmatic study by Lilly (LLY) and UnitedHealth Group (UNH) is set to evaluate bamlanivimab in high-risk symptomatic patients who test positive for COVID-19

Kinjel Shah headshot

Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates

Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.

Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US

With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).

AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure

AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.

Ritujay Ghosh headshot

COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap

Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.

RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US

RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.

Sheraz Mian headshot

Top Stock Reports for NVIDIA, Pfizer & Abbott

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Pfizer (PFE) and Abbott Laboratories (ABT).

Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

Regeneron's (REGN) Cocktail Gets EUA for COVID-19 by FDA

Regeneron's (REGN) antibody cocktail gets Emergency Use Authorization by the FDA for the treatment of COVID-19.

The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer

The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer

Should Value Investors Choose Eli Lilly and Co (LLY) Stock?

Let's see if Eli Lilly and Co (LLY) stock is a good choice for value-oriented investors right now from multiple angles.

Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada

Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.

AstraZeneca's (AZN) sBLA for New Imfinzi Dosage Gets Approval

AstraZeneca's (AZN) Imfizni is now available in monthly, fixed-dose regimen as alternative to twice-monthly, weight-based regimen for all three approved indications.

Gilead (GILD) Down on COVID-19 Drug Remdesivir Update

Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.

Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19

Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.

Stock Market News for Nov 20, 2020

U.S. stock markets closed higher on Thursday on hopes of restarting of Congressional negotiations for a fresh tranche of fiscal stimulus.

Kinjel Shah headshot

Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More

Pfizer (PFE) COVID-19 vaccine candidate proves to be 95% effective in final analysis. Sanofi (SNY), Lilly (LLY), Merck (MRK) & Glaxo (GSK) provide FDA updates.

Ritujay Ghosh headshot

What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?

Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.

RedHill (RDHL) to Begin Study on Second Coronavirus Candidate

The FDA clears RedHill's (RDHL) IND filing for a phase II/III study on its second coronavirus candidate RHB-107 to treat patients with symptomatic COVID-19 who do not require hospitalization.

RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study

Redhill (RDHL) completes enrollment in the phase II study on opaganib in patients hospitalized with severe COVID-19 pneumonia.

Stock Market News for Nov 17, 2020

Wall Street closed sharply higher on Monday buoyed by positive developments on coronavirus treatment front.